$CDIX Cashflow Statement | Understand Stock

$CDIX

$0.12 -$0.08 (41.9%) Close

$CDIX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2016 12 months to Dec 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss from operations
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Gain from disposal of fixed assets
Amortization of loan discount
Credit losses
Change in estimate for settlement realization rate
Amortization of debt discount
Gain on resolution and disposition of discontinued operations claims
Conversion and note issuance cost
Share issuance for compensation to directors and officers
Loss on disposal of assets
Interest included in line of credit
Share issuance and compensation expense
Other (income) or loss
Goodwill impairment
Loss on finance penalties and fees
Gain on refinance of debt
Gain on forgiveness of debt
Bonus expense settled with promissory notes
Gain on settlement or forgiveness of debt
Change in value of derivative liability
Stock based compensation
Convertible note issued for services rendered

(Increase) decrease in:
Accounts receivable
Inventory
Deposits
Right of use – assets
Prepaids and other current assets
Land

Increase (decrease) in:
Accounts payable
Accrued expenses
Accounts payable and accrued expense
Due to from related party
Due to related party
Accrued officers compensation
Accrued interest
Tax payable
Accrued payroll taxes
Deferred revenue
Right of use – liabilities

Net cash used in operating activities
Proceeds on sale of fixed assets
Net cash provided by Discontinued Operations – Operating
Purchase of property and equipment
Net cash provided by (used in) investing activities
Acquisition of Nova Ortho and Spine PLLC, net of cash acquired
Net cash (used in) investing activities
FINANCING ACTIVITIES
Due from/to related party
Proceeds from sales of stock
Proceeds from notes payable
Proceeds from notes payable - related party
Repayments to directors and officers
Payments to director
Proceeds from convertible notes payable
Proceeds from PPP loan and SBA loans
Net cash provided by financing activities
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD
CASH AND CASH EQUIVALENTS - END OF PERIOD
Proceeds from convertible notes payable
Payments on convertible notes payable
Dividend on preferred stock
Issuance of preferred stock
Repayment on SBA loans
Payments on note payable
Net proceeds from line of credit
Repayment of line of credit
Payment of dividend on preferred stock
Payment of dividends on preferred stock
Net cash provided by financing activities
NET (DECREASE) INCREASE IN CASH
CASH, BEGINNING OF YEAR
CASH, END OF YEAR
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the year for interest
NON-CASH INVESTING AND FINANCING ACTIVITIES*:
Common stock issued upon conversion of notes payable
Cash carried over from acquisition
Common stock issued for settlement of accrued expense
Preferred stock issued for business acquisition
Preferred stock issued upon conversion of notes payable and accrued interest
Preferred stock issued upon exchange of defaulted convertible notes payable
Derivative liability settled upon conversion
Common stock issued upon conversion of preferred stock
Series Y preferred stock issued in exchange of convertible notes payable
Accrued dividends on series Y preferred stock
Dividends on preferred stock, including accrued dividends on preferred stock
Promissory note payable issued in settlement agreement
Right of use assets acquired
Promissory notes payable issued in settlement of bonuses
Discount on convertible notes payable
Unearned compensation on restricted common stock grant

Comments